Published on 30/11/2025

Quality Agreements in Review: Refresh Triggers

In the highly regulated pharmaceutical industry, managing supplier and contract manufacturing organization (CMO/CDMO) relationships is critical. An effective quality agreement is a cornerstone of supplier qualification and oversight. This article outlines the necessary steps and refresh triggers that professionals in pharmaceutical quality assurance (QA), clinical operations, regulatory affairs, and medical affairs should consider for ongoing reviews. We will also explore how risk scoring, validation deliverables, and vendor audits fit into these processes under the guidelines of ICH Q10 and 21 CFR Part 11.

Main Objectives of Quality Agreements

A quality agreement is a formal document that defines each party’s responsibilities concerning product quality, regulatory compliance, and expectations for the manufacture and testing of a product. This document helps streamline communication, protect intellectual property, and establish clear expectations between parties. The primary objectives include:

• Define roles and responsibilities: Clearly outline what each party is responsible for in terms of compliance, manufacturing, and quality control.
• Regulatory compliance: Ensure that both parties comply with applicable regulations such as the FDA, EMA, and other relevant authorities.
• Risk Management: Include risk scoring and mitigation strategies to manage potential areas of concern effectively.

Establishing these objectives from the outset facilitates smoother collaboration and enhances product quality, thereby minimizing compliance risks.

Identifying Refresh Triggers

Over time, changes in business operations, regulations, and market conditions may necessitate a refresh of existing quality agreements. Identifying specific triggers for review is crucial to ensure compliance and continued performance. Here are several refresh triggers to consider:

• Change in Ownership or Structure: A shift in ownership or organizational structure of either party may require an update to existing agreements to reflect new responsibilities.
• Regulatory Changes: Updates in regulations, such as revisions to 21 CFR Part 11, may necessitate a review to ensure compliance with current standards.
• Performance Issues: A decline in product quality or service performance warrants an evaluation of the quality agreement.
• New Products or Services: Introduction of new products or services may require modifications to existing agreements to reflect new roles and responsibilities.
• Scheduled Reviews: Establish a timeline for periodic review (e.g., annually) to ensure that quality agreements remain relevant and effective.

Incorporating these triggers into your routine assessments helps ensure that quality agreements evolve in line with business needs and regulatory expectations.

Engaging in Risk Scoring

Risk scoring is a pivotal part of pharmaceutical supplier qualification and oversight. It aids in the systematic evaluation of potential risks associated with suppliers and CMOs/CDMOs, which is essential for tailoring quality agreements. The following steps outline how to effectively engage in risk scoring:

Step 1: Risk Identification

Conduct comprehensive risk identification to determine the types of risks that might be associated with the supplier or the service they provide. This includes evaluating:

• Quality issues, such as product defects or non-conformance to specifications.
• Operational risks, like delays in production or failures in compliance with timelines.
• Financial risks, including cost fluctuations or potential insolvency issues.
• Market risks, such as changes in demand for specific products or services.

Step 2: Risk Assessment

Once risks are identified, assess their potential impact and likelihood. Utilize a scoring system that evaluates both dimensions, allowing for easy prioritization. Commonly used parameters include:

• Severity: The potential impact on product quality or compliance status.
• Likelihood: The probability of the risk occurring in the context of historical performance data.

Step 3: Risk Control

Develop strategies for mitigating identified risks, which may include:

• Implementing enhanced vendor audits to monitor compliance closely.
• Establishing clear performance metrics within the quality agreement.
• Increasing frequency of communication and reporting with the vendor.

Step 4: Ongoing Review of Risks

Continuous monitoring and reassessment of risks is necessary. Update risk scores based on new information or performance evaluations and adjust the quality agreement clauses accordingly. This iterative process reinforces compliance and quality assurance.

Validation Deliverables in CMO Oversight

Validation deliverables represent key documentation that supports the assurance of quality and compliance throughout the lifecycle of the product being manufactured or serviced. In the context of CMO/CDMO oversight, essential deliverables include:

• Process Validation Protocols: These documents outline the procedures for validating each stage of the manufacturing process, including equipment used and critical process parameters.
• Method Transfer Packages: They encompass all necessary documentation to facilitate the transfer of methodologies and ensure equivalence between labs or facilities.
• Validation Reports: Reports generated post-validation activities that summarize findings, highlight deviations, and confirm that validation standards have been met.
• Risk Mitigation Plans: Plans that detail how identified risks will be managed and mitigated throughout the manufacturing process.

Effective management and review of these deliverables are critical for establishing robust oversight and maintaining compliance with regulatory standards.

Vendor Audits: Essential Element of Compliance

Conducting vendor audits is a foundational activity within supplier oversight. These audits provide comprehensive assessments of a vendor’s operations, quality management systems, and compliance with quality agreement clauses. Below are steps to ensure effective vendor audits:

Step 1: Audit Planning

Plan the audit meticulously, including scope, objectives, and schedule. Key elements of planning include:

• Identifying critical areas for evaluation based on risk scores.
• Establishing a timeline and assembling an audit team with the right expertise.
• Preparing necessary documentation, including previous audit findings and agreements.

Step 2: Audit Execution

During the audit, follow a structured approach to ensure all relevant aspects are assessed:

• Engage with key personnel to discuss processes and procedures.
• Observe operations in real-time to ensure adherence to documented procedures.
• Review relevant documentation, including batch records and quality control reports.

Step 3: Findings and Recommendations

Post-audit, compile findings, and formulate recommendations for improvement. Key steps include:

• Documenting areas of non-compliance or concerns identified during the audit.
• Prioritizing recommendations based on potential impact on quality and compliance.
• Providing a structured report to the vendor outlining findings and expectations for corrective actions.

Step 4: Follow-up

After delivering the audit report, schedule follow-up activities to ensure corrective actions have been implemented efficiently. This may include re-evaluation audits or progress reviews against established KPIs.

Conclusion

Quality agreements play a vital role in the oversight of suppliers, CMOs, and tech providers in the pharmaceutical industry. By implementing a structured approach to refresh triggers, risk scoring, validation deliverables, and vendor audits, companies can assure compliance and enhance the overall quality management system. This consistent oversight aligns with industry regulations from authorities like the FDA and EMA and reinforces a culture of continuous improvement across the entire supply chain.

Encouraging collaboration and clear communication across stakeholders is essential, particularly in the context of ongoing review processes. This focus on rigorous structuring and execution ensures that quality agreements remain effective and supportive of business objectives in an evolving regulatory landscape.